Bayers Investigational Darolutamide Plus ADT Significantly Extends MetastasisFree Survival in Phase 3 Study of NonMetastatic CastrationResistant Prostate Cancer

Bayer’s Investigational Darolutamide Plus ADT Significantly Extends Metastasis-Free Survival in Phase 3 Study of Non-Metastatic Castration-Resistant Prostate Cancer

10:04 EST 15 Feb 2019 | Speciality Pharma Journal

WHIPPANY, N.J., Feb. 14, 2019 /PRNewswire/ — Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant improvement in metastasis-free survival (MFS) with the investigational drug darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT (HR=0.41, 95% CI 0.34-0.50; P<0.001).2 This translates to a 59 percent reduction …

More From BioPortfolio on "Bayer’s Investigational Darolutamide Plus ADT Significantly Extends Metastasis-Free Survival in Phase 3 Study of Non-Metastatic Castration-Resistant Prostate Cancer"